A Phase II Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of A Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF) in Subjects With Clostridium Difficile Infection (CDI).

Trial Profile

A Phase II Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of A Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF) in Subjects With Clostridium Difficile Infection (CDI).

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2013

At a glance

  • Drugs Clostridium difficile vaccine (Primary)
  • Indications Clostridium infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 22 Dec 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-004907-69).
    • 29 Jun 2012 Actual patient number 116 added as reported by ClinicalTrials.gov.
    • 29 Jun 2012 Actual end date (1 Jun 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top